[go: up one dir, main page]

GB2503066B - Combination pharmaceutical composition and methods of treating and preventing the infectious diseases - Google Patents

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Info

Publication number
GB2503066B
GB2503066B GB1303867.4A GB201303867A GB2503066B GB 2503066 B GB2503066 B GB 2503066B GB 201303867 A GB201303867 A GB 201303867A GB 2503066 B GB2503066 B GB 2503066B
Authority
GB
United Kingdom
Prior art keywords
treating
preventing
methods
pharmaceutical composition
infectious diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1303867.4A
Other versions
GB2503066A (en
GB201303867D0 (en
GB2503066A8 (en
GB2503066B8 (en
Inventor
Alexandrovich Tarasov Sergey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45507292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2503066(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010133053/15A external-priority patent/RU2521392C2/en
Priority claimed from RU2010133043/15A external-priority patent/RU2519862C2/en
Priority claimed from RU2010133052/15A external-priority patent/RU2500422C2/en
Priority claimed from RU2010133047/15A external-priority patent/RU2517085C2/en
Priority claimed from RU2010133041/15A external-priority patent/RU2010133041A/en
Priority claimed from RU2010133051/15A external-priority patent/RU2505312C2/en
Priority claimed from RU2010133050/15A external-priority patent/RU2502521C2/en
Priority claimed from RU2011127226/15A external-priority patent/RU2577299C2/en
Priority to GB1707875.9A priority Critical patent/GB2548034B/en
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of GB201303867D0 publication Critical patent/GB201303867D0/en
Publication of GB2503066A publication Critical patent/GB2503066A/en
Publication of GB2503066B publication Critical patent/GB2503066B/en
Application granted granted Critical
Publication of GB2503066B8 publication Critical patent/GB2503066B8/en
Publication of GB2503066A8 publication Critical patent/GB2503066A8/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GB1303867.4A 2010-08-06 2011-07-15 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases Expired - Fee Related GB2503066B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1707875.9A GB2548034B (en) 2010-08-06 2011-07-15 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
RU2010133050/15A RU2502521C2 (en) 2010-08-06 2010-08-06 Combined drug for treating bacterial infections and method of treating bacterial infections
RU2010133052/15A RU2500422C2 (en) 2010-08-06 2010-08-06 Combined drug for treating viral infections and method of treating viral infections
RU2010133041/15A RU2010133041A (en) 2010-08-06 2010-08-06 INTEGRATED MEDICINE AND METHOD FOR PREVENTION OF HIV INFECTION, PREVENTION AND TREATMENT OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV, INCLUDING AIDS
RU2010133051/15A RU2505312C2 (en) 2010-08-06 2010-08-06 Combined therapeutic agent for treating various types of influenza
RU2010133053/15A RU2521392C2 (en) 2010-08-06 2010-08-06 Combined drug for treating viral infections and method of treating viral infections
RU2010133047/15A RU2517085C2 (en) 2010-08-06 2010-08-06 Complex medication and method of preventing hiv infection, prevention and treatment of hiv-induced and hiv-associated diseases, including aids
RU2010133043/15A RU2519862C2 (en) 2010-08-06 2010-08-06 Complex medication and method of prevention and treatment of infectious viral diseases
RU2011127226/15A RU2577299C2 (en) 2011-07-04 2011-07-04 Method for treating infectious diseases and complex medication for treatment of infectious diseases
PCT/IB2011/002470 WO2012017328A2 (en) 2010-08-06 2011-07-15 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Publications (5)

Publication Number Publication Date
GB201303867D0 GB201303867D0 (en) 2013-04-17
GB2503066A GB2503066A (en) 2013-12-18
GB2503066B true GB2503066B (en) 2017-09-06
GB2503066A8 GB2503066A8 (en) 2019-03-13
GB2503066B8 GB2503066B8 (en) 2019-03-13

Family

ID=45507292

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1303867.4A Expired - Fee Related GB2503066B8 (en) 2010-08-06 2011-07-15 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
GB1707875.9A Expired - Fee Related GB2548034B (en) 2010-08-06 2011-07-15 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1707875.9A Expired - Fee Related GB2548034B (en) 2010-08-06 2011-07-15 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Country Status (20)

Country Link
US (3) US20130045237A1 (en)
EP (1) EP2601219A2 (en)
JP (3) JP2013537532A (en)
KR (1) KR20140012021A (en)
CN (1) CN103154030A (en)
AU (1) AU2011287292B2 (en)
BR (1) BR112013002296A2 (en)
CZ (1) CZ2013159A3 (en)
DE (1) DE112011102640T5 (en)
EA (1) EA030513B1 (en)
ES (1) ES2510940R1 (en)
FR (1) FR2963563A1 (en)
GB (2) GB2503066B8 (en)
IL (1) IL224545A (en)
MX (1) MX368313B (en)
NZ (1) NZ606993A (en)
PE (1) PE20131185A1 (en)
PH (1) PH12013500232A1 (en)
SG (2) SG187732A1 (en)
WO (1) WO2012017328A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (en) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Method of treatment of pathological syndrome and medicinal agent
UA76638C2 (en) * 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (en) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Pressed solid oral formulation of medicinal preparation and method for preparing solid oral formulation of medicinal preparation
CZ2013105A3 (en) 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Method of increasing effect of antibody activated potentiated form
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
WO2012010970A2 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
AU2011281247B2 (en) * 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
CN103154030A (en) * 2010-08-06 2013-06-12 奥列格·伊里奇·爱泼斯坦 Compound pharmaceutical composition and method for treating and preventing infectious diseases
RU2535033C2 (en) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Therapeutic agent and method for prevention of hiv infection and treatment of hiv-caused or hiv-associated diseases, including aids
RU2013111961A (en) 2013-03-18 2014-09-27 Олег Ильич Эпштейн METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER
RU2013111962A (en) 2013-03-18 2014-09-27 Олег Ильич Эпштейн METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER
RU2603623C2 (en) * 2014-06-06 2016-11-27 Олег Ильич Эпштейн Veterinary composition and method for improving viability of animals, stimulation of body weight gain in mammals and birds, increasing efficiency of immunising, preventing and/or treating infectious diseases (versions)
DK4021505T3 (en) * 2019-08-29 2024-02-12 Oleg Iliich Epshtein DRUG FOR THE TREATMENT OF INFECTIOUS DISEASES
DE102020007979A1 (en) 2020-12-29 2022-06-30 Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie Composition for treating coronavirus infections
WO2023230249A1 (en) * 2022-05-25 2023-11-30 Baruch S. Blumberg Institute Novel hepatoselective polyadenylating polymerases inhibitors and their method of use
AU2023275550A1 (en) * 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
WO2025088452A1 (en) * 2023-10-24 2025-05-01 Epshtein Oleg Ilyich Artificial substance and method of its preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055518A1 (en) * 2001-12-26 2003-07-10 Goldberg, Evgeny Danilovich Method for curing immunopathosis and medicinal agent for carrying out said method
EP1550460A1 (en) * 2002-08-02 2005-07-06 Oleg Iliich Epshtein Method for correcting immune responses and medicinal agent
US20060024307A1 (en) * 2002-08-02 2006-02-02 Epshteni Oleg I Media and method for treating pathological syndrome
EP1997481A1 (en) * 2006-03-13 2008-12-03 Oleg Iliich Epshtein Solid oral form of a medicinal preparation and a method for the production thereof
EP2123300A1 (en) * 2007-02-02 2009-11-25 Dolgovykh, Lyudmila Fedorovna Medicinal agent for treating bird flu
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2192888C1 (en) 2001-02-15 2002-11-20 Эпштейн Олег Ильич Medicinal agent and method of treatment of pathological syndrome
UA76641C2 (en) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Homeopathic medicinal agent and method for curing diseases of prostate
TWI345470B (en) 2003-03-14 2011-07-21 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
EP2094300B1 (en) * 2006-12-22 2012-12-26 Rajesh Shah Medicinal formulation for the treatment for hepatitis c
EP2593474A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
DE112011102349T5 (en) * 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmaceutical composition and method of treatment
BR112013001299A2 (en) * 2010-07-21 2017-11-21 Lliich Epshtein Oleg pharmaceutical compositions and their use and methods of treating diabetes and related diseases in a human patient
BR112013001296A2 (en) * 2010-07-21 2017-12-19 Lliich Epshtein Oleg pharmaceutical compositions and their use and methods of treating vertigo of different origins, kinetosis and vegetative vascular dystonia
AU2011281247B2 (en) * 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
CN103154030A (en) * 2010-08-06 2013-06-12 奥列格·伊里奇·爱泼斯坦 Compound pharmaceutical composition and method for treating and preventing infectious diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome
WO2003055518A1 (en) * 2001-12-26 2003-07-10 Goldberg, Evgeny Danilovich Method for curing immunopathosis and medicinal agent for carrying out said method
EP1550460A1 (en) * 2002-08-02 2005-07-06 Oleg Iliich Epshtein Method for correcting immune responses and medicinal agent
US20060024307A1 (en) * 2002-08-02 2006-02-02 Epshteni Oleg I Media and method for treating pathological syndrome
EP1997481A1 (en) * 2006-03-13 2008-12-03 Oleg Iliich Epshtein Solid oral form of a medicinal preparation and a method for the production thereof
EP2123300A1 (en) * 2007-02-02 2009-11-25 Dolgovykh, Lyudmila Fedorovna Medicinal agent for treating bird flu

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Annals of Internal Medicine (2003); Vol 138, pp 393-399, "A critical overview of homeopathy", Jonas et al *
Hepatology (1998); Vol 27, pp 1128-1135, "ombination therapy with thymosin alpha1 and interferon...", Sherman et al *
Journal of Alternative & Complementary Medicine (2000); Vol 6, pp 49-56, "Clinical trials of homeopathy and placebo...", Vickers *
Journal of Infection (2000); Vol 40, pp 42-48, "Clinical efficacy and safety of the orally...", Makela et al *
Lancet (2005); Vol 366, pp 726-732, "Are the clinical effects of homoeopathy placebo effects?...", Shang et al *

Also Published As

Publication number Publication date
WO2012017328A2 (en) 2012-02-09
JP2013537532A (en) 2013-10-03
ES2510940A2 (en) 2014-10-21
AU2011287292A1 (en) 2013-03-14
BR112013002296A2 (en) 2018-01-30
SG187732A1 (en) 2013-03-28
GB2503066A (en) 2013-12-18
CN103154030A (en) 2013-06-12
JP2018135370A (en) 2018-08-30
JP2016216478A (en) 2016-12-22
PH12013500232A1 (en) 2019-09-02
PE20131185A1 (en) 2013-10-05
CZ2013159A3 (en) 2013-06-12
DE112011102640T5 (en) 2013-07-11
SG10201403870XA (en) 2014-08-28
US20150023972A1 (en) 2015-01-22
NZ606993A (en) 2015-11-27
AU2011287292B2 (en) 2017-02-02
GB2548034A (en) 2017-09-06
GB2548034B (en) 2018-05-23
MX368313B (en) 2019-09-27
GB201707875D0 (en) 2017-06-28
ES2510940R1 (en) 2015-03-27
GB201303867D0 (en) 2013-04-17
GB2503066A8 (en) 2019-03-13
FR2963563A1 (en) 2012-02-10
KR20140012021A (en) 2014-01-29
US20130045237A1 (en) 2013-02-21
GB2503066B8 (en) 2019-03-13
IL224545A (en) 2017-11-30
EP2601219A2 (en) 2013-06-12
EA201300135A1 (en) 2014-03-31
MX2013001451A (en) 2013-09-26
EA030513B1 (en) 2018-08-31
US20150023980A1 (en) 2015-01-22
WO2012017328A3 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
GB2503066B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
IL253225B (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
HUE041553T2 (en) Methods and compositions for the treatment of monogenic diseases
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
IL236221A (en) Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
IL225471A0 (en) Compositions and methods for the prevention and treatment of cancer
LT3378862T (en) Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of multiple sclerosis
EP2655334A4 (en) Compositions and methods useful for treating diseases
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
GB201302652D0 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
PL2621520T3 (en) Collagenase g and collagenase h compositions for the treatment of diseases involving alterations of collagen
IL225793A0 (en) Methods and compositions for the treatment of insulin-associated medical conditions
GB2496800B (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
GB201302656D0 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
ZA201207226B (en) Compositions and methods for treating viral diseases
EP2480099A4 (en) Compositions and methods for the prevention and treatment of metabolic diseases
IL226939A (en) Diarylpyridazinone derivatives, preparation thereof and their use for the treatment of humans
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201003741D0 (en) Methods and therapeutic compositions

Legal Events

Date Code Title Description
R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20150522

Free format text: EXTENSION APPLICATION

Effective date: 20150331

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION APPLICATION

Effective date: 20150902

Free format text: EXTENSION ALLOWED

Effective date: 20150907

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20150925

Free format text: EXTENSION APPLICATION

Effective date: 20150922

APTC Appeals to the court

Free format text: APPEAL LODGED; APPEAL AGAINST THE DECISION OF THE COMPTROLLER DATED 29 OCTOBER 2015 WAS LODGED WITH THE PATENTS COURT ON 26 NOVEMBER 2015.

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20190715